MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients

Federica Rinaldi; Francesco Marchesi; Francesca Palombi; Andrea Pelosi; Anna Laura Di Pace; Andrea Sacconi; Irene Terrenato; Ombretta Annibali; Valeria Tomarchio; Mirella Marino; Maria Cantonetti; Sara Vaccarini; Elena Papa; Lorenzo Moretta; Francesco Bertoni; Andrea Mengarelli; Giulia Regazzo; Maria G Rizzo

doi:10.1111/bjh.17734

MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients

Br J Haematol. 2021 Nov;195(3):399-404. doi: 10.1111/bjh.17734. Epub 2021 Jul 28.

Authors

Federica Rinaldi¹, Francesco Marchesi², Francesca Palombi², Andrea Pelosi³, Anna Laura Di Pace³, Andrea Sacconi⁴, Irene Terrenato⁴, Ombretta Annibali⁵, Valeria Tomarchio⁵, Mirella Marino⁶, Maria Cantonetti⁷, Sara Vaccarini⁷, Elena Papa², Lorenzo Moretta³, Francesco Bertoni^{8

9}, Andrea Mengarelli², Giulia Regazzo¹, Maria G Rizzo¹

Affiliations

¹ Department of Research, Advanced Diagnostics and Technological Innovation, Oncogenomic and Epigenetic Unit, Translational Research Area, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
² Department of Clinical and Experimental Oncology, Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
³ Immunology Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
⁴ Department of Research, Advanced Diagnostics and Technological Innovation, Clinical Trial Center, Biostatistics and Bioinformatics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁵ Hematology and Stem Cell Transplantation Unit, University Campus Bio-Medico, Rome, Italy.
⁶ Department of Research, Advanced Diagnostics and Technological Innovation, Pathology Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
⁷ Hematology Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata (PTV) Foundation, Rome, Italy.
⁸ Faculty of Biomedical Sciences, Institute of Oncology Research, USI, Bellinzona, Switzerland.
⁹ Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

PMID: 34318932
DOI: 10.1111/bjh.17734

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive, heterogeneous neoplasm where prognostication and therapeutic decision are challenging. The available prognostic tools are not able to identify all patients refractory to treatment. MicroRNAs, small RNAs frequently deregulated in cancer, stably circulate in biofluids, representing interesting candidates for non-invasive biomarkers. Here we validated serum miR-22, an evolutionarily conserved microRNA, as a prognostic/predictive biomarker in DLBCL. Moreover, we found that its expression and release from DLBCL cells are related to therapy response and adversely affect cell proliferation. These results suggest that miR-22 is a promising complementary or even independent non-invasive biomarker for DLBCL management.

Keywords: DLBCL; biomarkers; circulating microRNAs; liquid biopsy; miR-22.

Publication types

Multicenter Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers, Tumor / blood
Cell Division / genetics
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Exosomes / chemistry
Genes, bcl-2
Genes, myc
Humans
Lymphoma, Large B-Cell, Diffuse / blood*
Lymphoma, Large B-Cell, Diffuse / drug therapy
Lymphoma, Large B-Cell, Diffuse / genetics
Lymphoma, Large B-Cell, Diffuse / mortality
MicroRNAs / blood*
Molecular Sequence Annotation
Prednisone / administration & dosage
Prognosis
Prospective Studies
Proto-Oncogene Proteins c-bcl-6 / genetics
RNA, Neoplasm / blood*
Rituximab / administration & dosage
Vincristine / administration & dosage

Substances

BCL6 protein, human
Biomarkers, Tumor
MIRN22 microRNA, human
MicroRNAs
Proto-Oncogene Proteins c-bcl-6
R-CHOP protocol
RNA, Neoplasm
Rituximab
Vincristine
Doxorubicin
Cyclophosphamide
Prednisone